Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Mesa and Ulmer Measure Methods for JAK Inhibitor Optimization in Myelofibrosis

November 19th 2020

In our exclusive interview, Dr. Mesa and Dr. Ulmer discuss the current roles of ruxolitinib and fedratinib in myelofibrosis, current guidance for JAK inhibitor dosing, the utility of re-exposure to JAK inhibitors, and clinical trial options.

Dr. El Chaer on the Limitations of JAK Inhibitors in Myelofibrosis

November 17th 2020

Firas El Chaer, MD, discusses the limitations of JAK inhibitors in myelofibrosis.

Dr. Mascarenhas on the Promise of Imetelstat in Myelofibrosis

November 4th 2020

John O. Mascarenhas, MD, discusses the promise of imetelstat in myelofibrosis.

New Strategies Improve Outcomes for Lower-Risk MDS

November 4th 2020

Myelodysplastic syndrome is a challenging and complicated disease with median outcomes ranging from 5.3 years in patients with lower-risk disease to just 8.4 months in the very high-risk population.

Dr. Mascarenhas on Limitations With JAK Inhibitors in Myelofibrosis

November 4th 2020

John O. Mascarenhas, MD, discusses limitations with JAK inhibitors in myelofibrosis.

Dr. Mesa on Management Strategies for MPNs

October 23rd 2020

Ruben A. Mesa, MD, discusses management strategies for patients with myeloproliferative neoplasms.

Dr. Masarova on Future Research in MPNs

October 19th 2020

Lucia Masarova, MD, discusses future research ​efforts in myeloproliferative neoplasms.

Dr. Mesa on the Rationale for the Earlier Use of Ruxolitinib in Myelofibrosis

October 16th 2020

Ruben A. Mesa, MD, discusses the rationale for the earlier use of ruxolitinib in myelofibrosis.

Nazha Navigates Emerging Approaches for Polycythemia Vera Post Hydroxyurea

October 16th 2020

Aziz Nazha, MD, discusses risk stratification in polycythemia vera, options that have emerged for patients, approaches to consider following hydroxyurea, and the need for agents that will reverse fibrosis in the bone marrow.

Dr. Bose on Current Treatment Options for Essential Thrombocythemia

October 15th 2020

Prithviraj Bose, MD, discusses current treatment options for essential thrombocythemia.

Dr. Mesa on Remaining Challenges Faced in MPN Treatment

October 15th 2020

Ruben A. Mesa, MD, discusses remaining challenges faced in the treatment of patients with myeloproliferative neoplasms.

Dr. Nazha on the Potential Role of Ropeginterferon Alfa-2b in Polycythemia Vera

October 14th 2020

Aziz Nazha, MD, discusses the potential role of ropeginterferon alfa-2b in polycythemia vera.

FDA Approval Sought for Pacritinib in Myelofibrosis With Severe Thrombocytopenia

October 13th 2020

A rolling submission of a new drug application for the JAK2/FLT3 inhibitor pacritinib has been initiated for patients with myelofibrosis and severe thrombocytopenia defined as platelet counts of less than 50,000 μL.

Dr. Rampal on Tools to Estimate Prognosis in Myelofibrosis

October 13th 2020

Raajit K. Rampal, MD, PhD, discusses available tools to estimate prognosis in myelofibrosis.

Dr. Nazha on the Risk of Progression to Myelofibrosis in Polycythemia Vera

October 9th 2020

Aziz Nazha, MD, discusses the risk of progression to myelofibrosis in patients with polycythemia vera.

Dr. Pemmaraju on the Potential Role of Novel Therapies in MPNs

October 8th 2020

Naveen Pemmaraju, MD, discusses the potential role of novel therapies in myeloproliferative neoplasms.

Dr. Verstovsek on the Different Phases of MPNs

October 6th 2020

Srdan Verstovsek, MD, PhD, discusses the different phases of myeloproliferative neoplasms.

Dr. Masarova on the Safety of JAK Inhibitor/Targeted Therapy Combos in Myelofibrosis

October 5th 2020

Lucia Masarova, MD, discusses the toxicities associated with the combination of JAK inhibitors and other targeted therapies in patients with myelofibrosis.

Pacritinib NDA Submission Planned for Myelofibrosis With Severe Thrombocytopenia

October 1st 2020

An agreement has been reached to submit a new drug application for the potential accelerated approval of the JAK2/FLT3 inhibitor pacritinib for use in patients with myelofibrosis and severe thrombocytopenia.

Dr. Rampal on Challenges With Targeting High-Risk Mutations in Myelofibrosis

September 28th 2020

Raajit K. Rampal, MD, PhD, discusses challenges with targeting high-risk mutations in patients with myelofibrosis.